Aquestive CEO Counts Down To FDA Decision: 132 Days, Or 88 Trading Days
Management calls speed Anaphylm's differentiator, keeps its pricing private and holds 2026 revenue guidance of $46 million to $50 million.
Aquestive Therapeutics, which makes dissolvable oral films and other non-injection medicines, is 132 days from the FDA goal date for its epinephrine film Anaphylm, CEO Dan Barber said on the company's third-quarter earnings call Wednesday. For investors, he said, that is "only 88 trading days."
A Year Defined By Execution
Barber, the company's president and chief executive, said management is keeping its expectation of an FDA decision by March 16, 2027. The agency assigned a six-month review, and the company is hopeful for an earlier decision but does not control the agency's timelines, he said. Barber added that there is nothing new to report on the review.
He described 2027 as a year of execution and named three markers of success: progress with payers on covered lives and coverage quality, physician uptake where sales reps call, and how many dollars are spent against the uptake achieved. Aquestive has held pre-approval talks with the top four pharmacy benefit managers, he said.
On pricing, Barber was blunt: it is "the one piece we're going to keep to ourselves for right now." Copay cards and a patient hub will be in the toolkit, he said.
Speed As The Selling Point
Barber said that for a person in a severe allergic reaction, stopping it fast is all that matters, and that speed is "the ultimate differentiator." Chief Medical Officer Dr. Matt Greenhawt said the film's heart-rate peak comes in about eight to 11 minutes, with blood pressure peaks at about five to eight. In the studies he cited, the earliest comparator heart-rate peak is around 11 minutes and the rest come "past 19 minutes."
Chief Commercial Officer Sherry Korczynski said about 75 representatives will call on roughly 8,000 top-tier allergists, plus some pediatricians and otolaryngologists. She would not give the split between sales force and digital promotion, saying major television advertising would come later as spending efficiency allows.
For the manufacturing side, Barber said Suboxone, one of the licensed products Aquestive makes for partners, is up year to date.
Cash, Guidance And Funding Triggers
Chief Financial Officer Ernie Toth said third-quarter revenue was $7.6 million, against $12.8 million a year earlier, mainly because of quarterly swings in Suboxone orders. Revenue for the first nine months rose 14% to $35.8 million. The third-quarter net loss was $16.5 million, or 13 cents a share, versus $15.4 million a year earlier.
Cash stood at $90.3 million on September 30, before a $10 million upfront payment from Eton, which licensed the seizure-rescue film Libervant. Toth said year-end cash should top $70 million, without counting contingent funding. If Anaphylm is approved and conditions are met, $75 million becomes available under the RTW agreement and $20 million under the Oaktree loan.
The company maintained 2026 guidance of $46 million to $50 million in revenue. Barber said Aquestive expects to file Anaphylm in Canada before year-end and in Europe in the first quarter.
New data on Anaphylm will be presented at the allergy college meeting in Phoenix this month, the company said.
Sources
- Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates — Yahoo Finance
- Aquestive Therapeutics: Q3 Earnings Snapshot | 11alive.com — Associated Press
- Aquestive Therapeutics GAAP EPS of -$0.18 misses by $0.06, revenue of $7.5M misses by $3.52M (AQST:NASDAQ) — seekingalpha.com
- Document — sec.gov
- Aquestive Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com